Welcome to our dedicated page for MindWalk Holdings news (Ticker: HYFT), a resource for investors and traders seeking the latest updates and insights on MindWalk Holdings stock.
MindWalk Holdings Corp. reports developments in Bio-Native AI drug discovery, biologics research, and AI-driven therapeutic development. Company updates center on its patented HYFT technology and LensAI platform, which combine biological sequence, structure, function, literature analysis, and wet-lab validation for biologics discovery workflows.
Recurring news themes include financial results, enterprise platform contracts, North American biologics services activity, and product or program updates. Announcements have covered B Cell Llama for VHH nanobody discovery, B Cell Select, universal influenza research, functional-adjacency analysis for AI-designed therapeutics, and antibody or intrabody discovery work involving pathogenic TDP-43 in neurodegenerative disease.
MindWalk (NASDAQ: HYFT) reported Q2 fiscal 2026 results and strategic progress on its AI-driven pipeline on December 15, 2025. Key financials: Revenue $4.1M (+54% YoY, +30% sequential), gross margin 65% (from 51%), gross profit $2.7M (+94% YoY), adjusted EBITDA loss improved to $2.4M, and operating loss excluding amortization improved to $2.8M. Cash and cash equivalents were $16.5M, including proceeds from the sale of Netherlands operations.
Strategic updates: AI-designed GLP1 receptor agonist showed in vitro activation above semaglutide; a companion longevity pathway was identified; a conserved dengue epitope was discovered with preclinical planning underway; the company completed a rebrand, appointed a new CFO and CBO, closed a Netherlands divestiture for $14.3M, and initiated a Cayman structure to ringfence AI program portfolios with investor interest ahead of a January 12, 2026 strategic update.
MindWalk Holdings (NASDAQ:HYFT) will release second quarter fiscal 2026 financial results and host a live webcast and conference call on December 15, 2025 at 10:30 AM ET.
The company said a press release with the quarterly financial results will be issued prior to the call, followed by management remarks and a question-and-answer session. The live webcast and replay will be available via the company investor events page and an attendee URL is provided for access.
Dial-in numbers and a conference ID are provided for participants; investors are encouraged to review the company's periodic reports on sec.gov and sedarplus.com for risk factors and historical results.
MindWalk (Nasdaq: HYFT) announced that CTO Dr. Dirk Van Hyfte will participate in a fireside chat during the Biology Session at the AI Drug Discovery & Development Summit 2025 on November 20, 2025, 12:15 PM–12:45 PM. Dr. Van Hyfte will discuss how MindWalk’s HYFT®-powered LensAi™ platform indexes, connects, and continuously updates biological knowledge to support AI-driven drug discovery. The company frames the appearance as an opportunity to share its Bio-Native AI approach and Deep Data capabilities with industry peers and researchers.
MindWalk (Nasdaq: HYFT) appointed Thomas W. Lynch, Ph.D., as Chief Business Officer effective October 20, 2025 to accelerate commercial expansion of its HYFT-powered Deep Data platform.
Dr. Lynch brings over two decades of biotech and software commercialization experience, including roles at Aldevron and DNASTAR. He led commercial teams tied to Aldevron initiatives that contributed to its $9.6B acquisition by Danaher in 2021. MindWalk said the hire supports scaling global teams and forging strategic partnerships to broaden adoption in pharma and biotech markets.
MindWalk (NASDAQ: HYFT) announced a Board‑authorized share repurchase program to buy up to 2.3 million common shares between October 15, 2025 and October 15, 2026. The authorization equals approximately 5% of the 46,154,188 shares currently outstanding. Purchases may occur on the open market or by other legally permissible means at prevailing market prices, subject to U.S. and Canadian securities rules. The company expects to fund the Program from existing cash, short‑term investments, future cash flows, or financing activities. The Program is discretionary and does not obligate any repurchases; the Board may suspend or change its terms at any time.
MindWalk Holdings (NASDAQ:HYFT) has announced a significant advancement in its AI-designed GLP-1 therapeutics program, unveiling a novel dual-pathway regimen for aging and longevity applications. The company's LensAI™ platform has identified a previously unknown connection between GLP-1 biology and a second pathway crucial for healthy aging.
The breakthrough involves a first-in-class treatment approach combining MindWalk's proprietary companion therapeutic with its GLP-1 receptor agonists (GLP-1RAs). This development targets the longevity therapeutics market, projected to reach $60 billion by 2030. Earlier this year, the company's AI-designed GLP-1 peptides demonstrated performance matching or exceeding semaglutide in receptor activation assays.
MindWalk Holdings Corp. (NASDAQ: HYFT), formerly ImmunoPrecise Antibodies, reported strong financial results for Q1 FY2026. The Bio-Native AI company achieved record revenue of $7.6 million, representing a 45% year-over-year growth, with continuing operations contributing $3.2 million.
Key financial metrics showed significant improvement with gross margin expanding to 53% and net loss narrowing to $3.0 million from $4.0 million last year. The company's cash position stands at $5.0 million, supplemented by $16.1 million in net proceeds from the Netherlands operations divestiture.
Strategic developments include the company's rebranding to MindWalk, advancement of their dengue vaccine program into preclinical manufacturing, and expanded validation of their LensAI platform for biologics development risk assessment.
MindWalk (NASDAQ: HYFT), a bio-native AI company focused on TechBio and drug discovery, will release its Q1 FY2026 financial results on September 15, 2025. The company will host a conference call and webcast at 10:30 AM ET to discuss quarterly results and business highlights.
The earnings call will include a management presentation followed by a Q&A session. Participants can join via phone using various dial-in numbers (US/International: +1-646-307-1963, Toll-free: 800-715-9871) with Conference ID 3224490, or through the webcast link available on the company's IR website.